700125P
Avanti
DMHCA
Avanti Research™ - A Croda Brand 700125P, powder
Synonyma:
N,N-dimethyl-3β-hydroxycholenamide
Přihlásitk zobrazení cen stanovených pro organizaci a smluvních cen
About This Item
Doporučené produkty
assay
>99% (TLC)
form
powder
packaging
pkg of 1 × 5 mg (700125P-5mg)
manufacturer/tradename
Avanti Research™ - A Croda Brand 700125P
shipped in
dry ice
storage temp.
−20°C
General description
N,N-dimethyl-3β-hydroxy-cholenamide (DMHCA) is a potent steroidal liver X receptor (LXR) ligand in vitro and in vivo. It is used to treat atherosclerosis.
N,N-dimethyl-3β-hydroxycholenamide (DHMCA) is a synthetic ligand for liver X receptor (LXR).
Application
DMHCA has been used as LXR activator to treat retinal endothelial cells in order to activate the sirtuin 1- liver X receptors (SIRT1-LXR) pathway.
It may be used as 3β-hydroxysterol-Δ24-reductase (DHCR24) inhibitor.
Biochem/physiol Actions
N,N-dimethyl-3β-hydroxycholenamide (DHMCA) halts cholesterol biosynthesis by inhibiting 3β-hydroxysterol-Δ24-reductase (DHCR24) enzyme. It may serve as a therapeutic agent for treating atherosclerosis, age-related macular degeneration and diabetic retinopathy.
DMHCA (N,N-dimethyl-3β-hydroxycholenamide) is a synthetic oxysterol and is an agonist for liver X receptors (LXR). It promotes cholesterol transport, expression of adenosine triphosphate (ATP) binding cassette transporters. DMHCA suppresses the proinflammatory cytokines stimulation, induced by oxysterol.
Packaging
5 mL Amber Glass Screw Cap Vial (700125P-5mg)
Legal Information
Avanti Research is a trademark of Avanti Polar Lipids, LLC
Storage Class
11 - Combustible Solids
Osvědčení o analýze (COA)
Vyhledejte osvědčení Osvědčení o analýze (COA) zadáním čísla šarže/dávky těchto produktů. Čísla šarže a dávky lze nalézt na štítku produktu za slovy „Lot“ nebo „Batch“.
Již tento produkt vlastníte?
Dokumenty související s produkty, které jste v minulosti zakoupili, byly za účelem usnadnění shromážděny ve vaší Knihovně dokumentů.
Liver X receptor agonist inhibits proliferation of ovarian carcinoma cells stimulated by oxidized low density lipoprotein
Gynecologic Oncology, 116(1), 109-116 (2010)
Synthetic LXR agonist attenuates plaque formation in apoE-/-mice without inducing liver steatosis and hypertriglyceridemia
Journal of Lipid Research, 50(2), 312-326 (2009)
Gene-selective modulation by a synthetic oxysterol ligand of the liver X receptor.
Journal of Lipid Research, 45(10), 1929-1942 (2004)
The mechanism of diabetic retinopathy pathogenesis unifying key lipid regulators, sirtuin 1 and liver X receptor
EBioMedicine, 22, 181-190 (2017)
Frontiers in pharmacology, 9, 827-827 (2018-08-10)
N,N-dimethyl-3β-hydroxycholenamide (DMHCA) is an experimental pharmaceutical and a steroidal liver X receptor (LXR) agonist, which does not induce undesired hepatic lipogenesis. Herein, DMHCA was evaluated for its retinal effects on normal C57BL/6J and Cyp27a1-/-Cyp46a1-/- mice; the latter having higher retinal
Náš tým vědeckých pracovníků má zkušenosti ve všech oblastech výzkumu, včetně přírodních věd, materiálových věd, chemické syntézy, chromatografie, analytiky a mnoha dalších..
Obraťte se na technický servis.